Related Experiment Video
Updated: May 14, 2026
09:15
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Hapten-Based Cancer Immunotherapy: From Immune Activation to Antitumor Activity
Iseulys Richert1, Lionel Chalus1, Benoit Pinteur1
1Brenus-Pharma, 69002 Lyon, France.
Cells
|May 13, 2026
Summary
Hapten-based immunotherapies enhance tumor antigen recognition, boosting antitumor immune responses. This approach shows promise in preclinical models and early clinical trials for cancer treatment.
Area of Science:
- Immunology
- Oncology
- Vaccine Development
Background:
- Hapten-based immunotherapies enhance tumor antigen immunogenicity.
- Chemical conjugation of haptens to antigens creates novel determinants for immune recognition.
Purpose of the Study:
- To explore the mechanisms and clinical potential of hapten-based immunotherapies.
- To evaluate the efficacy of hapten-modified antigens in preclinical and clinical settings.
Main Methods:
- Mechanistic studies on antigen uptake, dendritic cell maturation, and immune activation.
- Preclinical models assessing immune activation, tumor regression, and immune memory.
- Clinical trials using dinitrophenyl-modified autologous tumor cell vaccines.
Main Results:
- Haptenation enhances antigen uptake and immune cell maturation.
- Preclinical studies demonstrate robust immune activation and tumor regression.
- Clinical trials show delayed-type hypersensitivity, T-cell expansion, and a favorable safety profile.
Conclusions:
- Hapten-based immunotherapies are a feasible strategy for targeting poorly immunogenic tumors.
- Further randomized studies are needed to confirm clinical benefit.
- Emerging strategies aim to expand epitope diversity and enhance immune priming.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:22T Cell Activation and Clonal Selection
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
01:26Antigens Involved in Adaptive Immunity
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.